IRIS - Res&Arch Institutional Research Information System - Research & Archive

SIGGILLINO, ANNAMARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 332
EU - Europa 265
AS - Asia 50
Totale 647
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 331
IE - Irlanda 110
IT - Italia 55
HK - Hong Kong 24
SE - Svezia 22
CN - Cina 21
DE - Germania 19
RO - Romania 12
RU - Federazione Russa 12
FR - Francia 11
FI - Finlandia 8
UA - Ucraina 6
CH - Svizzera 5
SG - Singapore 3
CZ - Repubblica Ceca 2
GB - Regno Unito 2
IN - India 1
MX - Messico 1
PH - Filippine 1
RS - Serbia 1
Totale 647
Salva come PNG Salva come JPEG
Città #
Dublin 110
Chandler 96
San Mateo 33
Hong Kong 24
Medford 17
Princeton 17
Altamura 16
Andover 15
Lawrence 14
Bucharest 12
Perugia 12
Wilmington 10
San Paolo di Civitate 6
Ann Arbor 5
Beijing 5
Redmond 5
Houston 3
Lausanne 3
Moscow 3
Norwalk 3
Nürnberg 3
Rome 3
Saint Petersburg 3
Boardman 2
Costa Mesa 2
Kansas City 2
Nanjing 2
Singapore 2
Angeles 1
Asso 1
Changsha 1
Chaoyang 1
Fairfield 1
Frankfurt Am Main 1
Granarolo dell'Emilia e Viadagola 1
Guangzhou 1
Henderson 1
Los Angeles 1
Marsciano 1
Nagold 1
Padova 1
Redwood City 1
Tappahannock 1
Trevi 1
Totale 444
Salva come PNG Salva come JPEG
Nome #
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 70
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 53
Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition 51
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 46
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 45
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors 44
Variations in gene expression of lung macromolecules after induction chemotherapy for lung cancer 43
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 42
Modified gene expression of alveolar-capillar membrane, extracellular matrix and membrane proteins after induction chemotherapy for Non-Small Cell Lung Cancer 41
Liquid Biopsy in early Breast Cancer: A preliminary Report 41
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 37
Prognostic implications of epidermal growth factor receptor, KRAS and BRAF gene mutations in resected non-small cell lung cancer patients 36
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 35
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 34
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype 27
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 23
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 22
Totale 690
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194 0 0 0 0 0 0 0 0 0 0 3 1
2019/202030 1 7 2 1 0 3 0 5 1 8 2 0
2020/202157 1 2 8 0 26 4 0 1 7 3 4 1
2021/2022135 1 22 2 6 2 0 0 50 0 4 20 28
2022/2023325 17 58 8 22 28 21 0 13 141 0 16 1
2023/202471 8 10 4 8 0 2 24 0 0 3 12 0
Totale 690